1040:
Hedlund PO, Ala-Opas M, Brekkan E, Damber JE, Damber L, Hagerman I, Haukaas S, Henriksson P, Iversen P, Pousette A, Rasmussen F, Salo J, Vaage S, Varenhorst E (2002). "Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian
Prostatic
510:
Mikkola AK, Ruutu ML, Aro JL, Rannikko SA, Salo JO (July 1998). "Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate
298:
Hackman G, Taari K, Tammela TL, Matikainen M, Kouri M, Joensuu T, Luukkaala T, Salonen A, Isotalo T, Pétas A, Hendolin N, Boström PJ, Aaltomaa S, Lehtoranta K, Hellström P, Riikonen J, Korpela M, Minn H, Kellokumpu-Lehtinen PL, Pukkala E, Hemminki A (November 2019). "Randomised Trial of
Adjuvant
1084:
Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, Johansson R, Klarskov P, Lundbeck F, Rasmussen F, Varenhorst E, Viitanen J (2008). "Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the
846:
Salonen AJ, Taari K, Ala-Opas M, Sankila A, Viitanen J, Lundstedt S, Tammela TL (December 2014). "Comparison of intermittent and continuous androgen deprivation and quality of life between patients with locally advanced and patients with metastatic prostate cancer: a post hoc analysis of the
1004:
Hedlund PO, Henriksson P (March 2000). "Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The
Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study".
810:
Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL (January 2013). "Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects".
482:
Aro J, Ruutu M, Juusela H, Hansson E, Permi J (1993). "Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The
Finnprostate Group".
589:
Mikkola A, Aro J, Rannikko S, Ruutu M (March 2007). "Ten-year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy".
375:
Haapiainen R, Rannikko S, Alfthan O (October 1986). "Comparison of primary orchiectomy with oestrogen therapy in advanced prostatic cancer. A 2-year follow-up report of a national, prospective prostatic cancer study".
933:
Lukkarinen O, Kontturi M (June 1994). "Comparison of a long-acting LHRH agonist and polyoestradiol phosphate in the treatment of advanced prostatic carcinoma. An open prospective, randomized multicentre study".
411:
Aro JL, Haapiainen RK, Rannikko SA, Alfthan OS (May 1989). "High dose polyoestradiol phosphate with and without acetosalicylic acid versus orchiectomy in the treatment of prostatic cancer. Finnprostate Group".
774:
Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL (June 2012). "The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer".
268:
Haapiainen R, Rannikko S, Ruutu M, Ala-Opas M, Aro J, Ervasti J, Hansson E, Hurme K, Juusela H, Mäkinen J (1985). "Early results of the
Finnish Multicentre Study of Prostatic Cancer (Finnprostate)".
546:
Mikkola A, Aro J, Rannikko S, Oksanen H, Ruutu M (2005). "Cardiovascular complications in patients with advanced prostatic cancer treated by means of orchiectomy or polyestradiol phosphate".
447:
Haapiainen R, Rannikko S, Alfthan O (July 1990). "Comparison of primary orchiectomy and polyoestradiol phosphate in the treatment of advanced prostatic cancer. Finnprostate Group".
635:"A high pretreatment plasma oestradiol level is associated with a low risk of acute myocardial infarction in parenteral oestrogen therapy for locally advanced prostate cancer"
1149:
199:
890:
Aro J (1991). "Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population".
299:
Radiotherapy
Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension".
682:
Mikkola A, Aro J, Rannikko S, Ruutu M (2009). "Prognostic grouping of metastatic prostate cancer using conventional pretreatment prognostic factors".
727:"Pretreatment plasma testosterone and estradiol levels in patients with locally advanced or metastasized prostatic cancer. FINNPROSTATE Group"
1134:
743:
726:
194:
1139:
969:
Bishop MC, Lemberger RJ, Selby C, Lawrence WT (September 1989). "Oestrogen dosage in prostatic cancer: the threshold effect?".
229:
242:
231:
Parenteral
Oestrogens for Prostate Cancer: A Systematic Review of Clinical Effectiveness and Dose Response (CRD Report 33)
139:
165:
group also assessed polyestradiol phosphate 160 mg/month versus orchiectomy for advanced prostate cancer. The
116:
228:
Emmans Dean M, Norman G, Hodges Z, Ritchie G, Light K, Eastwood A, Langley R, Sydes M, Parmar M, Abel P (2006),
1144:
143:
133:
112:
87:
69:
170:
125:
96:
75:
61:
354:"Comparison of primary orchiectomy and estrogen therapy in advanced prostatic cancer - a 2 years follow-up"
157:
A related study, by the
Finnish Zoladex Multicentre Study Group, assessed polyestradiol phosphate versus
29:
104:
1110:
1066:
915:
872:
756:
707:
664:
615:
571:
353:
334:
1102:
1058:
1022:
986:
951:
907:
864:
828:
792:
748:
699:
656:
607:
563:
528:
492:
464:
429:
393:
326:
277:
238:
1094:
1050:
1014:
978:
943:
899:
856:
820:
784:
738:
691:
646:
599:
555:
520:
456:
421:
385:
316:
308:
57:
237:, York: Centre for Reviews and Dissemination/University of York/York Publishing Services,
41:
44:. The first publication by the group was in 1985 and the latest publication was in 2019.
982:
460:
425:
389:
162:
37:
1018:
1128:
651:
634:
524:
338:
1114:
919:
876:
760:
711:
619:
575:
1070:
668:
248:
108:
860:
824:
312:
56:
FinnProstate-1 (FinnProstate-I; Finnish
Multicentre Study of Prostatic Cancer) –
178:
174:
129:
83:
65:
1054:
788:
1098:
947:
695:
559:
903:
182:
158:
100:
1106:
1062:
1026:
868:
832:
796:
752:
744:
10.1002/(sici)1097-0045(19990515)39:3<175::aid-pros5>3.0.co;2-e
703:
660:
611:
567:
330:
990:
955:
911:
532:
496:
468:
433:
397:
281:
321:
603:
79:
52:
The studies conducted by the FinnProstate group include the following:
33:
166:
138:
FinnProstate-7 (FinnProstate-VII) – intermittent versus continuous
1085:
Scandinavian
Prostatic Cancer Group (SPCG) Study No. 5".
633:
Mikkola AK, Aro JL, Rannikko AS, Ruutu ML (May 2008).
223:
221:
219:
217:
215:
64:
80 mg/month (160 mg/month initially) versus
725:
Mikkola AK, Aro JL, Rannikko SA, Salo JO (May 1999).
173:
240 mg/month versus combined androgen blockade (
128:
240 month (320 mg/month initially) versus
352:Haapiainen R, Rannikko S, Alfthan O (April 1986).
200:Prostate Adenocarcinoma: TransCutaneous Hormones
60:150 μg/day (1 mg/day initially) plus
293:
291:
263:
261:
92:FinnProstate-3 (FinnProstate-III) – cancelled
8:
78:160 mg/month (with or without low-dose
121:FinnProstate-5 (FinnProstate-V) – cancelled
1150:Scientific organisations based in Finland
742:
650:
320:
211:
148:Other studies by the FinnProstate group
107:300 mg/day initially to prevent
7:
847:randomized FinnProstate Study VII".
124:FinnProstate-6 (FinnProstate-VI) –
95:FinnProstate-4 (FinnProstate-IV) –
74:FinnProstate-2 (FinnProstate-II) –
1041:Cancer Group (SPCG) Study No. 5".
983:10.1111/j.1464-410x.1989.tb06016.x
461:10.1111/j.1464-410x.1990.tb14872.x
426:10.1111/j.1464-410x.1989.tb05946.x
390:10.1111/j.1464-410x.1986.tb05461.x
195:Scandinavian Prostate Cancer Group
14:
652:10.1111/j.1464-410X.2007.07361.x
525:10.1046/j.1464-410x.1998.00688.x
185:) for advanced prostate cancer.
161:for advanced prostate cancer. A
36:who have conducted a series of
1:
1019:10.1016/s0090-4295(99)00580-4
1135:Clinical trial organizations
861:10.3109/21681805.2014.901410
825:10.1016/j.eururo.2012.07.040
313:10.1016/j.eururo.2019.07.001
140:androgen deprivation therapy
1166:
1055:10.1080/003655902762467549
789:10.1016/j.juro.2012.01.122
117:metastatic prostate cancer
1099:10.1080/00365590801943274
948:10.3109/00365599409180495
696:10.1080/00365590902836500
560:10.1080/00365590510031228
99:160 mg/month versus
144:advanced prostate cancer
134:advanced prostate cancer
88:advanced prostate cancer
70:advanced prostate cancer
26:FinnProstate Study Group
1140:Evidence-based medicine
904:10.1002/pros.2990180205
485:Ann Chir Gynaecol Suppl
171:polyestradiol phosphate
126:polyestradiol phosphate
97:polyestradiol phosphate
76:polyestradiol phosphate
62:polyestradiol phosphate
30:scientific researchers
1087:Scand J Urol Nephrol
1043:Scand J Urol Nephrol
936:Scand J Urol Nephrol
684:Scand J Urol Nephrol
548:Scand J Urol Nephrol
105:cyproterone acetate
604:10.1002/pros.20547
358:Journal of Urology
40:of treatments for
18:FinnProstate Group
270:Ann Chir Gynaecol
1157:
1119:
1118:
1081:
1075:
1074:
1037:
1031:
1030:
1001:
995:
994:
966:
960:
959:
930:
924:
923:
887:
881:
880:
843:
837:
836:
807:
801:
800:
771:
765:
764:
746:
722:
716:
715:
679:
673:
672:
654:
630:
624:
623:
586:
580:
579:
543:
537:
536:
507:
501:
500:
479:
473:
472:
444:
438:
437:
408:
402:
401:
372:
366:
365:
349:
343:
342:
324:
295:
286:
285:
265:
256:
255:
253:
247:, archived from
236:
225:
58:ethinylestradiol
28:, is a group of
1165:
1164:
1160:
1159:
1158:
1156:
1155:
1154:
1145:Prostate cancer
1125:
1124:
1123:
1122:
1083:
1082:
1078:
1039:
1038:
1034:
1003:
1002:
998:
968:
967:
963:
932:
931:
927:
889:
888:
884:
845:
844:
840:
809:
808:
804:
773:
772:
768:
724:
723:
719:
681:
680:
676:
632:
631:
627:
588:
587:
583:
545:
544:
540:
509:
508:
504:
481:
480:
476:
446:
445:
441:
410:
409:
405:
374:
373:
369:
351:
350:
346:
297:
296:
289:
267:
266:
259:
251:
245:
234:
227:
226:
213:
208:
191:
169:trial assessed
155:
50:
48:Clinical trials
42:prostate cancer
38:clinical trials
12:
11:
5:
1163:
1161:
1153:
1152:
1147:
1142:
1137:
1127:
1126:
1121:
1120:
1076:
1032:
996:
961:
925:
882:
838:
802:
783:(6): 2074–81.
766:
717:
674:
625:
581:
554:(4): 294–300.
538:
502:
474:
439:
403:
367:
344:
307:(5): 586–595.
287:
257:
243:
210:
209:
207:
204:
203:
202:
197:
190:
187:
154:
153:Related trials
151:
150:
149:
146:
136:
122:
119:
93:
90:
72:
49:
46:
13:
10:
9:
6:
4:
3:
2:
1162:
1151:
1148:
1146:
1143:
1141:
1138:
1136:
1133:
1132:
1130:
1116:
1112:
1108:
1104:
1100:
1096:
1092:
1088:
1080:
1077:
1072:
1068:
1064:
1060:
1056:
1052:
1049:(6): 405–13.
1048:
1044:
1036:
1033:
1028:
1024:
1020:
1016:
1013:(3): 328–33.
1012:
1008:
1000:
997:
992:
988:
984:
980:
976:
972:
965:
962:
957:
953:
949:
945:
941:
937:
929:
926:
921:
917:
913:
909:
905:
901:
897:
893:
886:
883:
878:
874:
870:
866:
862:
858:
855:(6): 513–22.
854:
850:
842:
839:
834:
830:
826:
822:
819:(1): 111–20.
818:
814:
806:
803:
798:
794:
790:
786:
782:
778:
770:
767:
762:
758:
754:
750:
745:
740:
737:(3): 175–81.
736:
732:
728:
721:
718:
713:
709:
705:
701:
697:
693:
690:(4): 265–70.
689:
685:
678:
675:
670:
666:
662:
658:
653:
648:
645:(9): 1090–5.
644:
640:
636:
629:
626:
621:
617:
613:
609:
605:
601:
598:(4): 447–55.
597:
593:
585:
582:
577:
573:
569:
565:
561:
557:
553:
549:
542:
539:
534:
530:
526:
522:
518:
514:
506:
503:
498:
494:
490:
486:
478:
475:
470:
466:
462:
458:
454:
450:
443:
440:
435:
431:
427:
423:
419:
415:
407:
404:
399:
395:
391:
387:
384:(5): 528–33.
383:
379:
371:
368:
363:
359:
355:
348:
345:
340:
336:
332:
328:
323:
318:
314:
310:
306:
302:
294:
292:
288:
283:
279:
276:(6): 277–83.
275:
271:
264:
262:
258:
254:on 2021-09-08
250:
246:
240:
233:
232:
224:
222:
220:
218:
216:
212:
205:
201:
198:
196:
193:
192:
188:
186:
184:
180:
176:
172:
168:
164:
160:
152:
147:
145:
141:
137:
135:
131:
127:
123:
120:
118:
114:
110:
106:
102:
98:
94:
91:
89:
85:
81:
77:
73:
71:
67:
63:
59:
55:
54:
53:
47:
45:
43:
39:
35:
31:
27:
23:
19:
1093:(3): 220–9.
1090:
1086:
1079:
1046:
1042:
1035:
1010:
1006:
999:
977:(3): 290–6.
974:
970:
964:
942:(2): 171–8.
939:
935:
928:
898:(2): 131–7.
895:
891:
885:
852:
849:Scand J Urol
848:
841:
816:
812:
805:
780:
776:
769:
734:
730:
720:
687:
683:
677:
642:
638:
628:
595:
591:
584:
551:
547:
541:
516:
512:
505:
488:
484:
477:
452:
448:
442:
420:(5): 512–4.
417:
413:
406:
381:
377:
370:
361:
357:
347:
322:10138/306830
304:
300:
273:
269:
249:the original
230:
156:
109:gonadotropin
51:
25:
21:
17:
15:
519:(1): 63–8.
455:(1): 94–7.
179:orchiectomy
175:triptorelin
130:orchiectomy
84:orchiectomy
66:orchiectomy
1129:Categories
364:(4): A339.
244:1900640376
206:References
111:flare) in
971:Br J Urol
513:Br J Urol
449:Br J Urol
414:Br J Urol
378:Br J Urol
339:199389424
183:flutamide
159:goserelin
101:buserelin
82:) versus
1115:38638336
1107:18432528
1063:12623503
1027:10699602
920:27915767
892:Prostate
877:24864704
869:24679247
833:22857983
813:Eur Urol
797:22498230
761:38212069
753:10334106
731:Prostate
712:24321902
704:19382005
661:18070186
620:20549248
612:17219379
592:Prostate
576:24752258
568:16261661
511:Group".
331:31375279
301:Eur Urol
189:See also
113:advanced
1071:2799580
1007:Urology
991:2679960
956:7939468
912:2006119
669:2843818
639:BJU Int
533:9698663
497:8291869
491:: 5–8.
469:2132303
434:2659136
398:3779355
282:4096480
163:British
80:aspirin
34:Finland
1113:
1105:
1069:
1061:
1025:
989:
954:
918:
910:
875:
867:
831:
795:
777:J Urol
759:
751:
710:
702:
667:
659:
618:
610:
574:
566:
531:
495:
467:
432:
396:
337:
329:
280:
241:
167:SPCG-5
103:(with
24:), or
1111:S2CID
1067:S2CID
916:S2CID
873:S2CID
757:S2CID
708:S2CID
665:S2CID
616:S2CID
572:S2CID
335:S2CID
252:(PDF)
235:(PDF)
181:plus
1103:PMID
1059:PMID
1023:PMID
987:PMID
952:PMID
908:PMID
865:PMID
829:PMID
793:PMID
749:PMID
700:PMID
657:PMID
608:PMID
564:PMID
529:PMID
493:PMID
465:PMID
430:PMID
394:PMID
327:PMID
278:PMID
239:ISBN
142:for
132:for
86:for
68:for
16:The
1095:doi
1051:doi
1015:doi
979:doi
944:doi
900:doi
857:doi
821:doi
785:doi
781:187
739:doi
692:doi
647:doi
643:101
600:doi
556:doi
521:doi
489:206
457:doi
422:doi
386:doi
362:135
317:hdl
309:doi
177:or
115:or
32:in
1131::
1109:.
1101:.
1091:42
1089:.
1065:.
1057:.
1047:36
1045:.
1021:.
1011:55
1009:.
985:.
975:64
973:.
950:.
940:28
938:.
914:.
906:.
896:18
894:.
871:.
863:.
853:48
851:.
827:.
817:63
815:.
791:.
779:.
755:.
747:.
735:39
733:.
729:.
706:.
698:.
688:43
686:.
663:.
655:.
641:.
637:.
614:.
606:.
596:67
594:.
570:.
562:.
552:39
550:.
527:.
517:82
515:.
487:.
463:.
453:66
451:.
428:.
418:63
416:.
392:.
382:58
380:.
360:.
356:.
333:.
325:.
315:.
305:76
303:.
290:^
274:74
272:.
260:^
214:^
22:FP
1117:.
1097::
1073:.
1053::
1029:.
1017::
993:.
981::
958:.
946::
922:.
902::
879:.
859::
835:.
823::
799:.
787::
763:.
741::
714:.
694::
671:.
649::
622:.
602::
578:.
558::
535:.
523::
499:.
471:.
459::
436:.
424::
400:.
388::
341:.
319::
311::
284:.
20:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.